drugset / Trial / NCT07606833

The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori

NCT07606833

Phase 3 Not yet recruiting 556 enrolled Xuanzhu Biopharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double blind, double-simulated, parallel control of positive drug phase III clinical study to evaluate the efficacy and safety of Anaprazole versus Esomeprazole-containing Bismuth quadruple therapy for eradication of Helicobacter pylori in China.

Timeline

Start
2026-06-10
Primary completion
2027-02-19
Completion
2027-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Anaprazole Other / unclassified 20 mg Oral
Comparator Esomeprazole Small molecule 20 mg Oral
Background Amoxicillin Other / unclassified 1000 mg Oral
Background Bismuth Potassium Citrate Unknown 240 mg Oral
Background Clarithromycin Small molecule 500 mg Oral